Skip to content

EU rules for clinical studies of drugs and biologics

Oak
A river delta at dawn splits into channels, each lined with glowing flowers of one colour, with wading birds in the water.

A clinical trial of a medicinal product for human use in the European Union requires prior authorisation. Regulation (EU) No 536/2014 sets the rules, and Article 4 subjects a trial to scientific and ethical review before it may be authorised.1 The scientific assessment is carried out by the Member States concerned on a single application dossier submitted through the EU portal referred to in Article 80. The ethical review is performed by an ethics committee in accordance with the law of the Member State concerned.1

When a study falls under the Regulation

Whether a given study is a clinical trial within the scope of the Regulation is settled at the validation stage. Under Article 5(3) the reporting Member State notifies the sponsor, within 10 days of submission, whether the trial applied for falls within the scope of the Regulation under point (a) and whether the dossier is complete in accordance with Annex I under point (b).1 Other Member States concerned may communicate considerations relevant to validation within seven days of submission.1 Where the reporting Member State does not notify the sponsor within the applicable period, the trial is deemed to fall within the scope of the Regulation and the dossier is considered complete.1

Low-intervention clinical trials remain inside the authorisation system. Article 6(1)(a) requires the reporting Member State to assess whether the trial is a low-intervention trial where the sponsor claims that status.1 Article 5(2) adds a constraint on the choice of reporting Member State for a low-intervention trial in which the investigational medicinal product is used outside the terms of its marketing authorisation on an evidence-based footing. In that case the sponsor proposes as reporting Member State one of the Member States concerned where the use is evidence-based.1

The application and the reporting Member State

The sponsor submits one application dossier through the EU portal to the intended Member States concerned and proposes one of them as reporting Member State.1 Where another Member State concerned is willing to take that role, or where the proposed reporting Member State does not wish to take it, this is notified through the EU portal to all Member States concerned within three days of submission.1 If only one Member State concerned is willing, or if the trial involves a single Member State, that State is the reporting Member State. Where there is no agreement among several willing States, the proposed reporting Member State takes the role.1 The reporting Member State notifies the sponsor and the other Member States concerned of its role through the EU portal within six days of submission.1

If the reporting Member State finds the dossier incomplete or the trial outside scope, it informs the sponsor and sets a maximum of 10 days for comments or completion.1 It then notifies the sponsor within five days of receiving that response. Where the sponsor fails to respond within the period set, the application is deemed to have lapsed in all Member States concerned.1 The date of notification under Article 5(3) or 5(5) is the validation date, from which the assessment timelines run.1

Part I of the assessment report

Part I is assessed by the reporting Member State on behalf of all Member States concerned. Article 6(1) lists the aspects covered.1

  • whether the trial is a low-intervention clinical trial, where the sponsor claims that status
  • compliance with Chapter V as regards the anticipated therapeutic and public health benefits and the risks and inconveniences for the subject
  • compliance with the requirements on manufacture and import of investigational and auxiliary medicinal products in Chapter IX
  • compliance with the labelling requirements in Chapter X
  • the completeness and adequateness of the investigator’s brochure

The conclusion states that conduct of the trial is acceptable, acceptable subject to specific conditions listed in the conclusion, or not acceptable.1 The final Part I report goes to the sponsor and the other Member States concerned within 45 days of the validation date, and that submission fixes the reporting date.1 For multinational trials the 45 days break into an initial assessment phase of 26 days, a coordinated review phase of 12 days involving all Member States concerned and a consolidation phase of seven days.1

Two extensions apply. The reporting Member State may extend the 45-day period by a further 50 days for trials involving an advanced therapy investigational medicinal product or a product covered by point 1 of the Annex to Regulation (EC) No 726/2004, for the purpose of consulting experts.1 Between the validation date and the reporting date, only the reporting Member State may request additional information, and it may extend the period by a maximum of 31 days for that purpose.1 The sponsor is given a period not exceeding 12 days from receipt of the request. Failure to supply the information in time causes the application to lapse in all Member States concerned.1

Part II of the assessment report

Part II is assessed by each Member State concerned for its own territory. Article 7(1) sets out the aspects.1

  • compliance with the informed consent requirements in Chapter V
  • compliance of the arrangements for rewarding or compensating subjects and investigators
  • compliance of the arrangements for recruitment of subjects
  • compliance with Directive 95/46/EC
  • compliance with Article 49
  • compliance with Article 50
  • compliance with Article 76
  • compliance with the applicable rules on the collection, storage and future use of biological samples

Each Member State concerned completes its Part II assessment within 45 days of the validation date and submits the report to the sponsor through the EU portal.1 A request for additional information may be made only within that period, with justified reasons. The Member State may then extend the period by a maximum of 31 days, the sponsor replies within a period not exceeding 12 days, and the assessment is completed within a maximum of 19 days.1 Where the sponsor does not reply in time, the application lapses in that Member State alone.1

The authorisation decision

Each Member State concerned notifies the sponsor of a single decision through the EU portal within five days of the reporting date or of the last day of the Part II assessment, whichever is later.1 Authorisation subject to conditions is limited to conditions which by their nature cannot be fulfilled at the time of authorisation.1 A positive Part I conclusion is deemed to be the conclusion of each Member State concerned. A Member State may disagree only on three grounds: that participation would lead to a subject receiving inferior treatment compared with normal clinical practice in that State, infringement of its national law as referred to in Article 90, or considerations on subject safety and data reliability raised during the coordinated review.1

A Member State concerned refuses authorisation where one of those grounds applies, where it finds on duly justified grounds that Part II aspects are not complied with, or where an ethics committee has issued a negative opinion valid for that entire Member State under national law.1 An appeal procedure must be available against such a refusal. Where the reporting Member State concludes that the trial is not acceptable, that conclusion binds all Member States concerned.1 Silence works in the sponsor’s favour at this stage: if no decision is notified within the period in Article 8(1), the Part I conclusion is deemed to be the decision of that Member State.1

An authorisation does not last indefinitely without use. Article 8(9) provides that the authorisation expires in a Member State concerned if no subject has been included there within two years of the notification date, unless an extension has been approved on request of the sponsor under the procedure in Chapter III.1

Conditions for conducting the trial

Article 28(1) sets eight cumulative conditions for conduct of a trial. They cover the benefit-risk justification under constant monitoring and information and informed consent under Article 29. They also cover protection of the subject’s rights to integrity, privacy and data protection. A further condition is a design that involves as little pain, discomfort and fear as possible, with the risk threshold and the degree of distress defined in the protocol and constantly monitored.1 Medical care of subjects is the responsibility of an appropriately qualified medical doctor or, where appropriate, a qualified dental practitioner. Subjects must receive contact details of an entity from which further information can be obtained. No undue influence of any kind, including financial, may be exerted on them.1

A subject may withdraw at any time by revoking consent, without detriment and without giving a justification.1 Withdrawal does not affect activities already carried out or the use of data obtained on the basis of consent before withdrawal. The sponsor may separately ask the subject to consent to use of the data outside the protocol for scientific purposes, and that consent may also be withdrawn at any time.1

Consent is written, dated and signed by the subject or the legally designated representative and by the person who conducted the prior interview.1 Where the subject is unable to write, consent may be given and recorded by appropriate alternative means in the presence of at least one impartial witness, who signs and dates the document. The subject or representative receives a copy and must be allowed adequate time to consider participation.1

The information given must be comprehensive, concise, clear, relevant and understandable to a layperson, and must be prepared in writing and available to the subject.1 It covers the following.

  • the nature, objectives and benefits of the trial
  • its risks and inconveniences
  • the right to refuse and to withdraw
  • the conditions and expected duration of participation
  • the possible treatment alternatives

It also includes the applicable damage compensation system referred to in Article 76(1), the EU trial number and information on the availability of results.1 The interview is conducted by a member of the investigating team who is appropriately qualified under the law of the Member State concerned, and understanding must be verified during that interview.1

National law may go further in two respects. It may require the signature of an incapacitated person alongside that of the legally designated representative. It may also require the assent of a minor who is capable of forming an opinion and assessing the information given, in addition to the representative’s consent.1

Safety reporting during the trial

The sponsor reports suspected unexpected serious adverse reactions electronically and without delay to the database referred to in Article 40(1).1 The obligation covers reactions occurring in the trial whether at a Union site or in a third country, certain reactions to the same active substance in trials run exclusively in third countries by the same sponsor or a connected sponsor, and reactions coming to the sponsor’s attention after the end of the trial.1 Fatal or life-threatening reactions are reported as soon as possible and no later than seven days after the sponsor became aware. Other reactions are reported within 15 days, and a reaction later found to be fatal or life-threatening is reported within seven days of that becoming known.1 An initial incomplete report followed by a complete report is permitted in accordance with section 2.4 of Annex III.1

Annual safety reporting runs in parallel. The sponsor submits an annual report on the safety of each investigational medicinal product other than placebo through the same database.1 A single report may cover several investigational medicinal products used in one trial where the protocol so provides. The report contains only aggregate and anonymised data, and the obligation runs from the first authorisation of a trial under the Regulation until the end of the last trial conducted by that sponsor with the product.1

Trials started under Directive 2001/20/EC

Article 98 provided two transitional routes away from Directive 2001/20/EC. Trials whose authorisation request was submitted under the Directive before the Regulation’s date of application continued to be governed by the Directive for three years from that date.1 A second derogation allowed trials submitted within a defined window to start under Articles 6, 7 and 9 of the Directive and to remain under it for 42 months after publication of the notice referred to in Article 82(3), or until 28 May 2019 where that publication occurred before 28 November 2015.1 Both periods have expired. Authorisation and conduct of clinical trials in the Union now proceed under Regulation (EU) No 536/2014 alone.1

Questions people also ask

Does a clinical trial need a separate approval in every EU Member State where it runs?

The sponsor files one dossier through the EU portal for all intended Member States concerned, and each of those States issues one decision on the trial in its territory.1 The Part I assessment is performed once by the reporting Member State, and its positive conclusion is deemed to be the conclusion of each Member State concerned. A Member State may depart from that conclusion only on the grounds listed in Article 8(2), and a negative Part I conclusion binds all Member States concerned.1

How long does clinical trial authorisation take in the EU?

Validation takes up to 10 days from submission, with a further round of up to 15 days where the dossier needs completion.1 Both Part I and Part II assessments run for 45 days from the validation date, and the decision follows within five days of the later of the reporting date and the end of the Part II assessment.1 Requests for additional information add up to 31 days to either part, and expert consultation on advanced therapy products may add a further 50 days to Part I.1

What happens if a sponsor misses a deadline for answering questions during assessment?

The consequence depends on which part of the assessment is involved. Failure to supply additional information requested by the reporting Member State under Article 6(8) causes the application to lapse in all Member States concerned.1 Failure to answer a Part II request under Article 7(3) causes it to lapse only in the Member State that asked. Failure to complete the dossier at validation causes the application to lapse in all Member States concerned.1

Who carries out the ethical review of a clinical trial in the EU?

Ethical review is performed by an ethics committee in accordance with the law of the Member State concerned.1 The review may cover aspects addressed in Part I and in Part II of the assessment report, as appropriate for each Member State. Member States must ensure that the timelines and procedures of their ethics committees are compatible with those set out in the Regulation.1 A negative opinion that is valid for an entire Member State under national law obliges that State to refuse authorisation.1

How quickly must a suspected unexpected serious adverse reaction be reported?

Fatal or life-threatening reactions are reported to the database referred to in Article 40(1) as soon as possible and in any event within seven days of the sponsor becoming aware.1 Non-fatal and non-life-threatening reactions are reported within 15 days. Where a reaction initially assessed as non-fatal turns out to be fatal or life-threatening, the seven-day clock runs from the sponsor becoming aware of that change.1

Can a clinical trial authorisation lapse before the trial starts?

Yes. Where no subject has been included in a Member State concerned within two years of the notification date of the authorisation, the authorisation expires in that Member State.1 The sponsor may request an extension, which is approved following the procedure in Chapter III.1

Footnotes

  1. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance. Consolidated version of 2022-12-05. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02014R0536-20221205 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40 ↩41 ↩42 ↩43 ↩44 ↩45 ↩46 ↩47 ↩48 ↩49 ↩50 ↩51 ↩52 ↩53 ↩54 ↩55 ↩56 ↩57 ↩58 ↩59 ↩60 ↩61 ↩62 ↩63 ↩64 ↩65

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.